- Home
- AAP vs GLPG Comparison
AAP vs GLPG Comparison
Compare AAP & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AAP | GLPG |
|---|---|---|
| Founded | 1929 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | AAP | GLPG |
|---|---|---|
| Price | $38.72 | $32.64 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 20 | 4 |
| Target Price | ★ $52.08 | $31.33 |
| AVG Volume (30 Days) | ★ 1.9M | 84.4K |
| Earning Date | 02-25-2026 | 02-11-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,624,327,000.00 | $336,643,201.00 |
| Revenue This Year | N/A | $1.76 |
| Revenue Next Year | $1.08 | $0.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.31 |
| 52 Week Low | $28.89 | $22.36 |
| 52 Week High | $70.00 | $37.78 |
Technical Indicators
Market Signals| Indicator | AAP | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 28.71 | 55.51 |
| Support Level | $37.89 | $32.42 |
| Resistance Level | $40.71 | $33.24 |
| Average True Range (ATR) | 1.58 | 0.65 |
| MACD | -0.22 | 0.06 |
| Stochastic Oscillator | 10.45 | 72.59 |
Price Performance
Historical ComparisonAbout AAP Advance Auto Parts Inc.
Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About half of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on the basis of inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.